Designing Decentralised Clinical Trials for Patient Diversity
Data shows that most DCT approaches significantly improve patient diversity. This analysis examines what the evidence means for clinical trial design strategy.
“The pharma industry is beginning to look at biological age as a surrogate endpoint to improve clinical trials."
Explore expert-led podcasts, pharmaceutical intelligence, life sciences insights and research-driven analysis from leading industry voices. Pharmatica delivers trusted biotech news, drug development trends and commercial intelligence for professionals across the pharmaceutical sector.
Data shows that most DCT approaches significantly improve patient diversity. This analysis examines what the evidence means for clinical trial design strategy.
Choosing the wrong RWE data source undermines your regulatory strategy. This framework helps pharma leaders select the right real-world data collection method based on your programme’s research question.
By directly stimulating the visual cortex instead of relying on the retina or optic nerve, ReVision's FDA Breakthrough Device-designated implant could make vision restoration possible for millions of patients who have no existing treatment options.
Dr David Hayes explains why clinical research should be embedded early in cardiac device development and not treated as a late-stage compliance step.
Decentralised clinical trials expand access and reduce patient burden. Learn how sponsors balance innovation in DCT design, data integrity, and regulatory compliance.
What do pharma R&D tech investment committees really fund? Learn how workflow fit, enterprise pull, and strategic relevance drive adoption.
Explore the critical differences between preclinical vs clinical research, and how closing the translation gap can reduce drug development attrition and improve R&D decision-making.
Find out why strategic pharma intelligence is needed to connect insights and to guide confident decision-making across the drug development lifecycle.